ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Janssen to pay up to $1 billion for BeneVir

by Lisa M. Jarvis
May 4, 2018 | APPEARED IN VOLUME 96, ISSUE 19

 

Janssen Biotech, an arm of Johnson & Johnson, will pay $140 million up front to acquire BeneVir Biopharm, a privately held firm developing oncolytic immunotherapies. BeneVir investors could get another $900 million if certain milestones are met. BeneVir was founded on technology discovered by NYU School of Medicine professor Ian Mohr. The firm engineers oncolytic viruses—which infect and kill cancer cells—to not be killed by the immune system.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment